Video Interview: Market Leaders Show - Silexion's CEO Discusses Precision Cancer Treatment News & Recent Financing" (NASDAQ: SLXN)
Sharing this latest interview with Silexion CEO Ilan Hadar. Full link to interview on youtube: https://www.youtube.com/watch?v=1TaFQjlfILA, or watch it below
Summary:
In an insightful episode of Market Leaders, Ilan Hadar, Chairman and CEO of Silexion Therapeutics, shared the latest breakthroughs from the company’s cutting-edge oncology research. Silexion, a biotech firm focused on KRAS-driven cancers, recently announced compelling preclinical results for its lead candidate, SIL-204. The company’s latest data demonstrated SIL-204’s ability to significantly reduce tumor growth in pancreatic cancer models using systemic administration, an important milestone that could pave the way for treating metastatic cancers.
Hadar also discussed Silexion’s recent findings showing SIL-204’s synergy with standard chemotherapies like gemcitabine and irinotecan. The data suggests that SIL-204 could enhance the effectiveness of existing cancer treatments, underscoring its potential to transform the standard of care for pancreatic cancer patients.
Beyond its scientific advancements, Silexion has been making waves in the capital markets. The company ranked among the most actively traded U.S. stocks last week, with Nasdaq data showing trading volumes between 200 and 400 million shares on consecutive days. Hadar also provided insights into Silexion’s latest capital raise, a $3.3 million warrant exercise designed to strengthen the company’s balance sheet while minimizing shareholder dilution.
With its momentum in both science and the markets, Silexion is positioning itself as a leader in next-generation cancer therapeutics. For those looking to stay updated, the company trades on the NASDAQ under the ticker SLXN.
Full interview link: https://www.youtube.com/watch?v=1TaFQjlfILA
--
Our posts are not financial or investment advice. This content is shared on behalf of SLXN who is a paid subscriber to our coverage and distribution service. See full terms and conflicts: redditwire.com/terms